MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
Arbutus Biopharma Corporation (NASDAQ: ABUS)*
Organization & Developments: Arbutus Biopharma
Parents
Arbutus Biopharma Corporation (NASDAQ: ABUS)*
Children
*The company is focusing its efforts on developing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection as well as developing treatments for Covid.
2020: Biotech Analysis Central Preview Series: Arbutus Biopharma
2022: Arbutus Biopharma (ABUS) presents at AASLD 2022 - Slideshow_ seekingalpha.com
2022: Arbutus Biopharma: Long-Term Hold With Advancements Into Several Areas Of Interest_seekingalpha.com
2022: Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera_seekingalpha.com
2023 Arbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023_seekingalpha.com
2023: Arbutus Biopharma is cutting 24% of its staff, the company
2023: Putting Arbutus Biopharma Back In The Spotlight (NASDAQ:ABUS)
2024: UniQure, Arbutus and HilleVax all lay off staff as biotechs streamline operations and cut costs_
2025: Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Jumps
Finance & Acquisitions: Arbutus Biopharma
Key People: Arbutus Biopharma